CoChat
Sign Up
Cited by 371Fatty Acid Research and HealthCardiac electrophysiology and arrhythmiasCardiac pacing and defibrillation studies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Fish Oil Supplementation and Risk of Ventricular Tachycardia and Ventricular Fibrillation in Patients With Implantable Defibrillators: A Randomized Controlled Trial

Raitt, Merritt H., Connor, William E., Morris, Cynthia, Kron, Jack, Halperin, Blair, Chugh, Sumeet S., McClelland, James, Cook, James, MacMurdy, Karen, Swenson, Robert, Connor, Sonja L., Gerhard, Glenn, Kraemer, Dale F., Oseran, Daniel, Marchant, Christy, Calhoun, David, Shnider, Reed, McAnulty, John·2005·JAMA
DOI 10.1001/jama.293.23.2884
Open this paper in CoChat — free account

Abstract

CONTEXT: Clinical studies of omega-3 polyunsaturated fatty acids (PUFAs) have shown a reduction in sudden cardiac death, suggesting that omega-3 PUFAs may have antiarrhythmic effects. OBJECTIVE: To determine whether omega-3 PUFAs have beneficial antiarrhythmic effects in patients with a history of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF). DESIGN AND SETTING: Randomized, double-blind, placebo-controlled trial performed at 6 US medical centers with enrollment from February 1999 until January 2003. PATIENTS: Two hundred patients with an implantable cardioverter defibrillator (ICD) and a recent episode of sustained VT or VF. INTERVENTION: Patients were randomly assigned to receive fish oil, 1.8 g/d, 72% omega-3 PUFAs, or placebo and were followed up for a median of 718 days (range, 20-828 days). MAIN OUTCOME MEASURES: Time to first episode of ICD treatment for VT/VF, changes in red blood cell concentrations of omega-3 PUFAs, frequency of recurrent VT/VF events, and predetermined subgroup analyses. RESULTS: Patients randomized to receive fish oil had an increase in the mean percentage of omega-3 PUFAs in red blood cell membranes from 4.7% to 8.3% (P<.001), with no change observed in patients receiving placebo. At 6, 12, and 24 months, 46% (SE, 5%), 51% (5%), and 65% (5%) of patients randomized to receive fish oil had ICD therapy for VT/VF compared with 36% (5%), 41% (5%), and 59% (5%) for patients randomized to receive placebo (P = .19). In the subset of 133 patients whose qualifying arrhythmia was VT, 61% (SE, 6%), 66% (6%), and 79% (6%) of patients in the fish oil group had VT/VF at 6, 12, and 24 months compared with 37% (6%), 43% (6%), and 65% (6%) of patients in the control group (P = .007). Recurrent VT/VF events were more common in patients randomized to receive fish oil (P<.001). CONCLUSION: Among patients with a recent episode of sustained ventricular arrhythmia and an ICD, fish oil supplementation does not reduce the risk of VT/VF and may be proarrhythmic in some patients.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.293.23.2884

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Raitt, M. H., Connor, W. E., Morris, C., Kron, J., Halperin, B., Chugh, S. S., McClelland, J., Cook, J., MacMurdy, K., Swenson, R., Connor, S. L., Gerhard, G., Kraemer, D. F., Oseran, D., Marchant, C., Calhoun, D., Shnider, R., & McAnulty, J.
Affiliations
  • Oregon Health & Science University (US)
  • Providence St. Vincent Medical Center (US)
  • Tufts University (US)
  • Oregon State University (US)
Corresponding author
Raitt, Merritt H.
ORCID
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2005-06-15
Volume
293
Issue
23
Pages
2884
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.293.23.2884
OpenAlex
W2099859189
Cited by
371
References
25
Citations by year
2025: 3 · 2024: 7 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 9 · 2019: 3 · 2018: 9 · 2017: 11 · 2016: 11 · 2015: 6 · 2014: 14 · 2013: 19 · 2012: 36
FWCI
40.55
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01hl061682-04)
  • National Heart, Lung, and Blood Institute (R01HL61682)
  • National Center for Research Resources (M01RR000334, 5M01 RR00334)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
Keywords
omega-3 polyunsaturated fatty acids, ventricular tachycardia, ventricular fibrillation, implantable cardioverter-defibrillator, antiarrhythmic effect, red blood cell membrane fatty acids, recurrent arrhythmia, sudden cardiac death, arrhythmia recurrence, omega-3 deficiency
MeSH terms
Aged, Double-Blind Method, Erythrocyte Membrane, Female, Humans, Male, Middle Aged, Prospective Studies, Risk, Ventricular Fibrillation, Fatty Acids, Omega-3, Proportional Hazards Models, Survival Analysis, Defibrillators, Implantable, Tachycardia, Ventricular, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review